As per DelveInsight analysis, the Dry Eye Disease market is anticipated to witness growth at a considerable CAGR.

LAS VEGAS, NEVADA, UNITED STATES, March 22, 2024 /EINPresswire.com/ -- DelveInsight’s “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Dry Eye Disease, historical and forecasted epidemiology as well as the Dry Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Dry Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Dry Eye Disease Market Forecast

Some of the key facts of the Dry Eye Disease Market Report:

The Dry Eye Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032).
In March 2023, Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced that it has entered into a research, development, and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease.Under the agreement, Selagine will receive an upfront payment and annual collaboration fee. In addition, Grifols has committed to fund the development of immunoglobulin eye drops through FDA approval, which will be managed collaboratively by Grifols and Selagine, including the clinical, manufacturing and regulatory activities required for FDA approval for dry eye disease indication.
In February 2023, Aldeyra Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for topical ocular reproxalap, a first-in-class investigational new drug candidate, for the treatment of the signs and symptoms of dry eye disease. The FDA assigned a Prescription Drug User Fee Act (PDUFA) date of November 23, 2023. The FDA noted that no potential filing review issues have been identified, and that an advisory committee meeting is not currently planned.
In February 2023, Novaliq, announced its plans for filing a Marketing Authorisation Application (MAA) for CyclASol^® (ciclosporin ophthalmic solution), a first-of-its-kind anti-inflammatory product for the treatment of dry eye disease (DED) in the European Union. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) determined that CyclASol^® is eligible to be reviewed in a centralized procedure to receive a Union Marketing Authorisation for the European Economic Area (EEA).
In January 2023, Bausch + Lomb Corporation and Novaliq GmbH, announced that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the pivotal Phase 3 trial GOBI, which is one of two pivotal Phase 3 trials for NOV03 (perfluorohexyloctane). NOV03 is being investigated to treat the signs and symptoms of dry eye disease (DED) associated with Meibomian gland dysfunction (MGD).In the study, NOV03 was well tolerated with few subjects experiencing ocular adverse events (AEs) (9.6% NOV03 group, 7.5% control group) or treatment-related ocular AEs (6.3% NOV03 group, 3.1% control group).
In August 2022, Alcon and Aerie Pharmaceuticals, Inc. announced the companies have entered into a definitive merger agreement through which Alcon acquired Aerie. The transaction affirmed Alcon's commitment to the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to Alcon's existing commercial expertise, maximizing the value of its diversified portfolio. Through the transaction, Alcon added the commercial products Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa^® (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates.
In May 2022, Yuyu Pharmaceutical presented a poster study for YP-P10, its new dry eye syndrome treatment, during the 2022 ARVO (Association for Research in Vision and Ophthalmology) conference. YP-P10 is a new biopharmaceutical using synthetic peptides, aiming to relieve signs and symptoms of dry eye syndrome caused by inflammation by administering the treatment twice a day. According to preclinical trial results unveiled at the conference, Yuyu confirmed that the candidate had an excellent anti-inflammatory mechanism and corneal epithelial cell healing effect compared to existing drugs.
Key Dry Eye Disease Companies: Alcon, Allysta Pharmaceuticals, Aramis Biosciences, BRIM Biotechnology, Dreamhawk Vision Biotech, Inc., HanAll Biopharma, Invirsa, IVIEW Therapeutics, Kowa Company, MC2 Therapeutics, Novaliq, Novaliq GmbH, Noveome, Ocular Therapeutix, Palatin Technologies, Quorum Innovations, Seikagaku Corporation, Seinda Pharmaceutical, Serentrix, Taejoon Pharmaceutical, and others.
Key Dry Eye Disease Therapies: OTX-DED (Ocular Therapeutix), HL036 (tanfanercept) (HanAll Biopharma/Daewoong Pharmaceutical, PL9643 (Palatin Technologies), and others
According to Dana et al. (2019), the overall Dry Eye Disease prevalence was 5.28%, wherein the prevalence among females and males was about 7.78% and 2.96%, respectively, in the US. Besides, the prevalence increased with age from 0.20%, for ages 2–17 years, to 11.66% for individuals aged above 50.
According to a study by Dalton et al. (2019), around 16 million Americans have been diagnosed with Dry Eye Disease, but the actual number of Americans suffering from dry eye symptoms is likely much higher. Some reports indicate that nearly half of all US adults experience dry eye signs and symptoms, and 33% of patients in eye care clinics present with complaints about dry eye.
According to the Association of Optometrists, dry eye is a very common condition in the UK, affecting one in four people in the UK.
The Dry Eye Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Dry Eye Disease pipeline products will significantly revolutionize the Dry Eye Disease market dynamics.

Dry Eye Disease Overview

Dry eye disease (DED), alternatively referred to as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a prevalent condition characterized by insufficient tear production or rapid evaporation of tears. Tears play a crucial role in lubricating and nourishing the eyes; thus, the condition results in dry, red, swollen, and irritated eyes. Causes of DED include reduced tear production, excessive tear evaporation, and abnormalities in tear layer mucus or lipid production.

The condition arises from a persistent lack of adequate lubrication and moisture on the eye surface, leading to a spectrum of consequences from mild, constant eye irritation to severe inflammation and potential scarring of the eye's front surface. Dry eye disease can affect one or both eyes and may result in inflammation.

The primary symptom of dry eye is a sensation of dryness and grittiness in the eyes. Additional symptoms encompass burning or itching sensations, feeling as if there's a foreign object in the eye, excessive tearing, eye pain and redness, and, occasionally, sensitivity to light. Stringy discharge and fluctuating or blurred vision may also occur. Moreover, symptoms typically worsen in dry weather conditions with low humidity and higher temperatures. Prolonged dry eye can cause tiny abrasions on the eye surface, and in advanced cases, pathological changes such as squamous metaplasia and loss of goblet cells may occur in the epithelium.

Dry Eye Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Dry Eye Disease Epidemiology Segmentation:

The Dry Eye Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Dry Eye Disease
Prevalent Cases of Dry Eye Disease by severity
Gender-specific Prevalence of Dry Eye Disease
Diagnosed Cases of Episodic and Chronic Dry Eye Disease

Download the report to understand which factors are driving Dry Eye Disease epidemiology trends @ Dry Eye Disease Epidemiology Forecast

Dry Eye Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Dry Eye Disease market or expected to get launched during the study period. The analysis covers Dry Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Dry Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Dry Eye Disease Therapies and Key Companies

A197: Aramis Biosciences
AR-15512: Aerie Pharmaceuticals
CLX-OPH-621: Cellix Bio
CyclASol: Novaliq GmbH
GLH8NDE: GL Pharm TechCorporation
HL036: HanAll Biopharma
INV-102: Invirsa
iVIEW 1001: IVIEW Therapeutics
K-161: Kowa Research Institute, Inc.
NOV03: Novaliq GmbH
OTX-DED: Ocular Therapeutix
Qi 401: Quorum Innovations
SER-114: Serentrix
SHJ 002: Dreamhawk Vision Biotech, Inc.
SI-614: Seikagaku Corporation
SY-201: Seinda Pharmaceutical
TJO-083: Taejoon Pharmaceutical Co., Ltd.
And Many More

Discover more about therapies set to grab major Dry Eye Disease market share @ Dry Eye Disease Treatment Landscape

Dry Eye Disease Therapeutics Analysis

The disease management aims to relieve the discomfort and prevent damage to the cornea, at the front of the eye. Currently, the available treatment options for Dry Eye Disease depend on the severity of the condition. They may include medication, surgery, and others (eyelid therapy [warm compresses and eyelid hygiene, contact lenses, and moisture chamber spectacles]).

Treatment depends on the underlying cause. Artificial tears are the usual first-line treatment. Wrap-around glasses that fit close to the face may decrease tear evaporation. Stopping or changing certain medications may help. The medication cyclosporine or steroid eye drops may be used in some cases. Another option is lacrimal plugs that prevent tears from draining from the surface of the eye. DES occasionally makes wearing contact lenses impossible. Various therapies like MIEBO (perfluorohexyloctane ophthalmic solution), XIIDRA (lifitegrast ophthalmic solution), and TYRVAYA nasal spray, among others are approved for the treatment of the signs and symptoms of dry eye disease.

The dynamics of the Dry Eye Disease market are anticipated to experience a positive shift in the coming years owing to the expected launch of a barrage of emerging therapies like OTX-DED (Ocular Therapeutix), HL036 (tanfanercept) (HanAll Biopharma/Daewoong Pharmaceutical, PL9643 (Palatin Technologies) and many others in the upcoming years.

Scope of the Dry Eye Disease Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Dry Eye Disease Companies: Alcon, Allysta Pharmaceuticals, Aramis Biosciences, BRIM Biotechnology, Dreamhawk Vision Biotech, Inc., HanAll Biopharma, Invirsa, IVIEW Therapeutics, Kowa Company, MC2 Therapeutics, Novaliq, Novaliq GmbH, Noveome, Ocular Therapeutix, Palatin Technologies, Quorum Innovations, Seikagaku Corporation, Seinda Pharmaceutical, Serentrix, Taejoon Pharmaceutical, and others
Key Dry Eye Disease Therapies: OTX-DED, HL036, PL9643, and others
Dry Eye Disease Therapeutic Assessment: Dry Eye Disease current marketed and Dry Eye Disease emerging therapies
Dry Eye Disease Market Dynamics: Dry Eye Disease market drivers and Dry Eye Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Dry Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Dry Eye Disease Market Access and Reimbursement
To know more about Dry Eye Disease companies working in the treatment market, visit @ Dry Eye Disease Clinical Trials and Therapeutic Assessment

Table of Contents

1. Dry Eye Disease Market Report Introduction
2. Executive Summary for Dry Eye Disease
3. SWOT analysis of Dry Eye Disease
4. Dry Eye Disease Patient Share (%) Overview at a Glance
5. Dry Eye Disease Market Overview at a Glance
6. Dry Eye Disease Disease Background and Overview
7. Dry Eye Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Dry Eye Disease
9. Dry Eye Disease Current Treatment and Medical Practices
10. Dry Eye Disease Unmet Needs
11. Dry Eye Disease Emerging Therapies
12. Dry Eye Disease Market Outlook
13. Country-Wise Dry Eye Disease Market Analysis (2019–2032)
14. Dry Eye Disease Market Access and Reimbursement of Therapies
15. Dry Eye Disease Market Drivers
16. Dry Eye Disease Market Barriers
17. Dry Eye Disease Appendix
18. Dry Eye Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

Dry Eye Disease Pipeline

"Dry Eye Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Dry Eye Disease market. A detailed picture of the Dry Eye Disease pipeline landscape is provided, which includes the disease overview and Dry Eye Disease treatment guidelines.

Dry Eye Disease Epidemiology

DelveInsight's 'Dry Eye Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Dry Eye Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

Kritika Rehani
DelveInsight Business Research LLP
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.